Elicio Therapeutics (ELTX) Free Cash Flow (2020 - 2026)
Elicio Therapeutics' (ELTX) quarterly Free Cash Flow came in at -$11.9 million in Q1 2026, down 17.3% YoY from -$14.4 million in Q1 2025, and down 78.68% on a QoQ basis from -$6.6 million in Q4 2025.
Elicio Therapeutics (ELTX) Free Cash Flow (2020 - 2026) Analysis & Trends
Elicio Therapeutics (ELTX) has 7 years of Free Cash Flow data on file, last reported at -$11.9 million in Q1 2026.
- Quarterly Free Cash Flow fell 17.3% year-over-year to -$11.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$38.7 million (down 9.65% YoY) and the FY2025 annual result came in at -$37.0 million, up 0.5% from the prior year.
- Free Cash Flow slipped to -$11.9 million in Q1 2026, from -$6.6 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $5.5 million in Q2 2022 to a low of -$15.6 million in Q1 2022.
- A 5-year average of -$8.3 million and a median of -$9.0 million in 2025 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2022 — Free Cash Flow jumped 152.71% — and 2023, when it slumped 270.82%.
- Tracing ELTX's Free Cash Flow over 5 years: stood at -$7.3 million in 2022, then plunged by 35.09% to -$9.8 million in 2023, then decreased by 12.56% to -$11.1 million in 2024, then surged by 39.96% to -$6.6 million in 2025, then plunged by 78.68% to -$11.9 million in 2026.
- The last three Free Cash Flow figures came in at -$11.9 million (Q1 2026), -$6.6 million (Q4 2025), and -$11.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Elicio Therapeutics | 58.41 Mn | 34.91 Mn | - | -8.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.00 Mn |
| Jun 30, 2026 | -8.00 Mn |
| Mar 31, 2026 | -11.87 Mn |
| Mar 31, 2026 | -11.87 Mn |
| Dec 31, 2025 | -6.64 Mn |
| Dec 31, 2025 | -6.64 Mn |
| Sep 30, 2025 | -11.26 Mn |
| Sep 30, 2025 | -11.26 Mn |
| Jun 30, 2025 | -8.95 Mn |
| Jun 30, 2025 | -8.95 Mn |
| Mar 31, 2025 | -10.12 Mn |
| Mar 31, 2025 | -10.12 Mn |
| Dec 31, 2024 | -11.06 Mn |
| Dec 31, 2024 | -11.06 Mn |
| Sep 30, 2024 | -6.24 Mn |
| Sep 30, 2024 | -6.24 Mn |
| Jun 30, 2024 | -7.89 Mn |
| Jun 30, 2024 | -7.89 Mn |
| Mar 31, 2024 | -11.96 Mn |
| Mar 31, 2024 | -11.96 Mn |